This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Orlistat in simple obesity

Authoring team

743 patients with BMI 28-47 were recruited.

There was an initial placebo run-in period of 4 weeks during which a mildly hypocaloric diet was commenced.

Only patients (668) who completed this run-in and who had taken more than 75% of their tablets were enrolled into the 1 year single-blind trial of orlistat in combination with a hypocaloric diet.

In the second year patient were re-randomised to orlistat or placebo in combination with a eucaloric diet (one designed to maintain a stable weight).

Reference:

  • 1) Sjostrom, L, Rissanen, A, Andersen, T. et al (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167-72.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.